Pharmaceutical group · United States
Pfizer
A group of 128 companies with 4,080 medicines in 12 countries.
Loading your page…
Loading your page…
Pharmaceutical group · United States
A group of 128 companies with 4,080 medicines in 12 countries.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
128 companies in 22 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 4,080
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| A-HYDROCORT100mg base/vial | 1gm base/vial | 250mg base/vial | 500mg base/vial · Injectable | Hydrocortisone | United States | Not marketed | 1978 |
| A-METHAPRED125mg base/vial | 1gm base/vial | 40mg base/vial | 500mg base/vial · Injectable | Methylprednisolone | United States | Not marketed | 1978 |
| ABRILADA10mg/0.2ml | 20mg/0.4ml | 40mg/0.8ml · Injectable | Adalimumab | United States | Marketed | 2019 |
| Abrilada40mg/0.8ml · Injection | Adalimumab | United States | Marketed | 2019 |
| ABRILADA40 mg / 0.8 ml · Solution | Adalimumab | Canada | Marketed | 2022 |
| Abrilada10mg/0.2ml · Injection | Adalimumab | United States | Not marketed | 2019 |
| ABRILADA40 mg / 0.8 ml · Kit, Solution | Adalimumab | Canada | Authorised | |
| ABRILADA10 mg / 0.2 ml · Solution | Adalimumab | Canada | Authorised | |
| ABRILADA40 mg / 0.8 ml · Solution | Adalimumab | Canada | Marketed | 2022 |
| ABRILADA20 mg / 0.4 ml · Solution | Adalimumab | Canada | Marketed | 2023 |
| ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 ML40mg/0.8ml · Injection, solution | Adalimumab | Singapore | Authorised | 2022 |
| ABRYSVO | Vacina vírus sincicial respiratório a e b | Brazil | Authorised | 2024 |
| Abrysvo | Respiratory syncytial virus vaccines | EU (EMA) | Authorised | 2023 |
| Abrysvo120ug · Injection | Respiratory syncytial virus vaccines | United States | Marketed | 2023 |
| ABRYSVO60 mcg / 0.5 ml + 60 mcg / 0.5 ml · Kit, Powder For Solution | Rsv subgroup a stabilized prefusion f protein, Rsv subgroup b stabilized prefusion f protein | Canada | Marketed | 2024 |
| ABRYSVOPolvere e solvente per soluzione iniettabile | Respiratory syncytial virus vaccines | Italy | Authorised | |
| Abrysvo poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Recombinant respiratoir syncytieel virus subgroep a prefusie f antigeen, Recombinant respiratoir syncytieel virus subgroep b prefusie f antigeen | Netherlands | Authorised | 2023 |
| Abrysvo poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Recombinant respiratoir syncytieel virus subgroep a prefusie f antigeen, Recombinant respiratoir syncytieel virus subgroep b prefusie f antigeen | Netherlands | Authorised | 2023 |
| ABRYSVO POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE0,06 mg + 0,06 mg · Polvo y disolvente para solución inyectable | Virus sincitial respiratorio, subgroupo a, subunidad f proteina estabilizada en prefusion, Virus sincitial respiratorio, subgroupo b, subunidad f proteina estabilizada en prefusion | Spain | Marketed | 2023 |
| ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION0.06 mg/vial + 0.06 mg/vial · Injection, powder, for solution | Rsv subgroup a stabilized prefusion f protein, Rsv subgroup b stabilized prefusion f protein | Singapore | Authorised | 2024 |
| ACCUPRIL10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG BASE * · Tablet | Quinapril | United States | Not marketed | 1991 |
| ACCURETIC12.5MG; 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 12.5MG; 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 25MG; 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness · Tablet | Hydrochlorothiazide, Quinapril | United States | Not marketed | 1999 |
| Aciclovir Hospira 25 mg/ml, concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Aciclovir | Netherlands | Authorised | 1999 |
| ACIDO ZOLEDRONICO HOSPIRAConcentrato per soluzione per infusione | Zoledronic acid | Italy | Authorised | |
| ADCETRIS50 mg / vial · Powder For Solution | Brentuximab vedotin | Canada | Marketed | 2013 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 1,083 | 278 | 805 | CompaniesAll medicines |
| United States | 648 | 643 | 5 | CompaniesAll medicines |
| Brazil | 516 | 85 | 431 | CompaniesAll medicines |
| Saudi Arabia | 444 | 444 | 0 | CompaniesAll medicines |
| Spain | 370 | 311 | 59 | CompaniesAll medicines |
| Romania | 241 | 0 | 241 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
| Netherlands | 221 | 221 | 0 | CompaniesAll medicines |
|---|
| Singapore | 165 | 165 | 0 | CompaniesAll medicines |
|---|
| Italy | 130 | 129 | 1 | CompaniesAll medicines |
|---|
| Serbia | 117 | 111 | 6 | CompaniesAll medicines |
|---|
| European Union (EMA) | 96 | 56 | 40 | CompaniesAll medicines |
|---|
| Croatia | 49 | 49 | 0 | CompaniesAll medicines |
|---|
Also in the registers of France, United Kingdom
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Companies House, Find and update company information; exact company number and page URL, accessed 8 October 2026. Structured factual extraction by Prognia. Crown-created website material under OGL 3.0: https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Licence: Companies House statutory public-register use; OGL 3.0 for Crown-created website material
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA factual register
GLEIF; exact source URLs/locators, version status and retrieval dates. Normalized by Prognia; no official endorsement.
Licence: CC0
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/847386/OFFICINE_API_GIUGNO_2025.csv; HTTP Last-Modified Tue, 08 Jul 2025 11:28:20 GMT; acquired 2026-10-13T17:21:05.497592+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/847386/officine_autorizzate_medicinali_30.06.2026.csv; HTTP Last-Modified Wed, 01 Jul 2026 09:37:30 GMT; acquired 2026-10-13T17:21:05.166252+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Ministero della Salute, Italy; https://www.dati.salute.gov.it/it/dataset/distributori-di-farmaci/; original CSV snapshot 15 October 2026, acquired 2026-10-15T13:26:43.659718+00:00; adapted factual fields under IODL2. Coordinates: © OpenStreetMap contributors, separate rights gate.
Licence: Italian Open Data Licence v2.0, exact dataset-catalog assignment; coordinate fields separately attributed to OpenStreetMap
Ministero della Salute, Distributori di farmaci, source file13Oct2026. https://www.dati.salute.gov.it/it/dataset/distributori-di-farmaci/; IODL2.0 https://www.dati.gov.it/content/italian-open-data-license-v20. Original URLs/locators and retrieval timestamps; selected/normalized by Prognia; no government endorsement.
Licence: Italian Open Data Licence
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Contains data under the Norwegian licence for Open Government data (NLOD) distributed by Brønnøysundregistrene. https://data.norge.no/nlod/en/2.0; original API URLs, retrieval dates and locators. Selected and normalized by Prognia; fractional JSON numbers preserved as labelled exact decimal strings.
Licence: Norwegian Licence for Open Government Data
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Saudi Food and Drug Authority (SFDA), local human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from ACRA Information on Corporate Entities, accessed on 8 October 2026 through Data.gov.sg, under Singapore Open Data Licence version 1.0: https://data.gov.sg/open-data-licence. Structured selection and normalisation by Prognia; original UEN, field and retrieval date retained.
Licence: Singapore Open Data Licence
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.